We are honored to have Dr. Joshua Schiffman as our keynote speaker at this years Investors Choice Conference. He will be talking about new discoveries that could lead to curing cancer!! So exciting!
Dr. Joshua Schiffman is a pediatric hematologist-oncologist at Intermountain Primary Children’s Hospital and Huntsman Cancer Institute (HCI) at the University of Utah. He attended the Brown University School of Medicine, followed by pediatric residency, chief residency, and pediatric hematology-oncology at Stanford University School of Medicine. While at Stanford, he began their Pediatric Cancer Genetics Program. Dr. Schiffman has been on the faculty at the University of Utah since 2008, where he is a Professor in Pediatrics and an Adjunct Professor in Oncological Sciences, he also holds the inaugural Edward B. Clark, MD Endowed Chair in Pediatric Research. Dr. Schiffman directs a translational genomics laboratory at HCI to identify who develops cancer and why. Most recently, Dr. Schiffman teamed up with collaborators from across the globe to compare the functional genomics of different species across the animal kingdom to guide cancer research. Dr. Schiffman published a landmark paper in JAMA about the genetic mechanism of cancer resistance in elephants. This work was featured as a cover story in Newsweek, as well as in over 20,000 different print and television. Dr. Schiffman recently co-founded PEEL Therapeutics with Dr. Avi Schroeder, chemical engineer from Technion-Israel Institute of Technology. Using patented nanotechnology drug delivery, PEEL Therapeutics will deliver the elephant cancer resistance genes directly to patients for cancer treatment and prevention. PEEL Therapeutics has just begun their first series round of funding.